Arvinas Q1 Revenue Plunges 92% to $15.6M, Swings to $57.6M Net Loss
ARVN sits 64% above its 52-week low of $5.9.
Summary
Arvinas reported first-quarter 2026 financial results showing a significant year-over-year decline, with revenue plummeting 91.7% to $15.6 million and the company swinging to a net loss of $57.6 million, or ($0.9) per diluted share, from a prior-year profit. This financial update follows the recent accelerated FDA approval of VEPPANU on May 1st, a major positive catalyst for the company. However, the company also noted it has paused direct launch activities for VEPPANU, with commercialization to be handled by a third party selected jointly with Pfizer. The substantial revenue drop and return to a significant net loss are material and could temper the positive sentiment from the recent regulatory success, raising questions about the immediate financial impact of VEPPANU and the company's operational efficiency. Investors will be closely watching for further details on the third-party commercialization strategy and how future quarters reflect VEPPANU's sales.
At the time of this announcement, ARVN was trading at $9.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $617.9M. The 52-week trading range was $5.90 to $14.51. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.